{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T19:53:17Z","timestamp":1790452397982,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since the discovery of calcitonin gene\u2010related peptide (CGRP) in 1982, its integral role in migraine pathophysiology, specifically migraine pain, has been demonstrated through cumulative scientific discoveries that have led to the development and approval of migraine\u2010specific therapeutics. Today, eight drugs, including monoclonal antibodies and small molecule CGRP receptor antagonists, known as gepants, have received approval for acute or preventive treatment of migraine. The primary mechanism of these drugs is to block CGRP signaling, thus preventing CGRP\u2010mediated nociception and neurogenic inflammation. Here, we focus on atogepant, a highly potent and selective gepant and the first and only oral medication approved for the preventive treatment of both episodic and chronic migraine in adults. In this article, we summarize the role of CGRP in migraine pathophysiology and the mechanism of action of atogepant. In addition, we provide an overview of atogepant's pharmacology and the key clinical trials and outcomes that have demonstrated the safety and efficacy of atogepant.<\/jats:p>","DOI":"10.1111\/cts.13707","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T12:55:07Z","timestamp":1704891307000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Atogepant: Mechanism of action, clinical and translational science"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-9210","authenticated-orcid":false,"given":"Ramesh","family":"Boinpally","sequence":"first","affiliation":[{"name":"Clinical Pharmacology AbbVie  North\u00a0Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-8933","authenticated-orcid":false,"given":"Mohamad","family":"Shebley","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie  North\u00a0Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-8878","authenticated-orcid":false,"given":"Joel M.","family":"Trugman","sequence":"additional","affiliation":[{"name":"Clinical Development AbbVie  North\u00a0Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynpai.2022.100094"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01217.x"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01363-y"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01637-7"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030505"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12618"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01525.x"},{"key":"e_1_2_13_11_1","volume-title":"Calcitonin Gene\u2010Related Peptide (CGRP) Mechanisms","year":"2019"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000831"},{"key":"e_1_2_13_13_1","unstructured":"Pradeep BanerjeeRB TrugmanJM.Pharmacological Pharmacodynamic and Pharmacokinetic Properties of Atogepant: A Potent and Selective CGRP Receptor Antagonist. Poster presented at: CGRP 10th International CGRP Family Peptides Conference. April 11\u201312 2022."},{"key":"e_1_2_13_14_1","unstructured":"QULIPTA (atogepant) [package insert]. North Chicago IL USA. AbbVie Inc. Updated June 2023. Accessed September 15 2023.https:\/\/www.rxabbvie.com\/pdf\/QULIPTA_pi.pdf"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221111526"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02939.x"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01049-8"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01644-5"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14439"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15499"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201568"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211042385"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77146"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221146315"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512268"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad261"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121180"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/pmt\u20102023\u20100056"},{"key":"e_1_2_13_30_1","unstructured":"AQUIPTA (atogepant) [Summary of Product Characteristics]. North Chicago IL USA. AbbVie Inc. Published August 2023. Accessed September 15 2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/aquipta\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_13_31_1","unstructured":"QULIPTA Product Monograph. AbbVie Canada. December 2022. Accessed September 15 2023.https:\/\/www.abbvie.ca\/content\/dam\/abbvie\u2010dotcom\/ca\/en\/documents\/products\/QULIPTA_PM_EN.pdf"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30234-9"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T18:43:52Z","timestamp":1706121832000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/cts.13707"],"URL":"https:\/\/doi.org\/10.1111\/cts.13707","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13707"}}